The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | How might tegavivint complement EGFR inhibition in lung cancer?
Regan Memmott, MD, PhD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, comments on the potential role of tegavivint with osimertinib in patients with metastatic stage 4 EGFR mutated non-small cell lung cancer (NSCLC). Whilst the combination is not yet clear on its effectiveness against other types of EGFR mutations, such as PACC mutations and exon 20 insertion mutations, increased beta-catenin and transcriptional activity may be a contributing factor to treatment persistence. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We really are looking at all patients with EGFR mutated lung cancer that have a classical EGFR mutation because we’re combining the tegavivint with osimertinib. It isn’t clear if, you know, you definitely see persistence with these other types of EGFR mutations like PACC mutations, exon 20 insertion mutations. Those treatments that are targeting EGFR are also not curative, there’s persistence, is it also due to increased beta-catenin and transcriptional activity? It might be and that could be something we pursue in the future but right now this combination is really for all patients with metastatic stage 4 EGFR mutated lung cancer...
We really are looking at all patients with EGFR mutated lung cancer that have a classical EGFR mutation because we’re combining the tegavivint with osimertinib. It isn’t clear if, you know, you definitely see persistence with these other types of EGFR mutations like PACC mutations, exon 20 insertion mutations. Those treatments that are targeting EGFR are also not curative, there’s persistence, is it also due to increased beta-catenin and transcriptional activity? It might be and that could be something we pursue in the future but right now this combination is really for all patients with metastatic stage 4 EGFR mutated lung cancer.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
